Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ifabotuzumab - Humanigen

Drug Profile

Ifabotuzumab - Humanigen

Alternative Names: Anti-EphA3 MAb; Anti-EphA3 monoclonal antibody; Humaneered antibody; IgG1-kappa antibody; IgG1K antibody; KB-004

Latest Information Update: 20 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Humanigen; Olivia Newton-John Cancer Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; EphA3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I Glioblastoma

Most Recent Events

  • 29 Mar 2019 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Glioblastoma presented at the 110th Annual Meeting of the American Association for Cancer Research
  • 04 Jan 2019 Pharmacodynamics data from a preclinical trial in Glioblastoma released by Humanigen
  • 21 Dec 2017 Ifabotuzumab - Humanigen is available for licensing as of 21 Dec 2017. www.humanigen.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top